Progress and controversies: Radiation therapy for invasive breast cancer

CA Cancer Journal for Clinicians

Volumn 64, Issue 2, 2014, Pages 135-152

  Jagsi, Reshma ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Breast conserving therapy; Hypofractionation; Intensity modulated radiotherapy; Partial breast irradiation; Postmastectomy radiation; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BRACHYTHERAPY; BREAST CANCER; BREAST RECONSTRUCTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; REVIEW; TREATMENT INDICATION; TUMOR INVASION;

BREAST CANCER; BREAST-CONSERVING THERAPY; HYPOFRACTIONATION; INTENSITY-MODULATED RADIOTHERAPY; PARTIAL BREAST IRRADIATION; POSTMASTECTOMY RADIATION; RADIATION THERAPY;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL;

EID: 84899461444     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21209     Document Type: Review

References (169)

1. National Institutes of Health (NIH). Treatment of Early-Stage Breast Cancer. NIH Consensus Statement Online. Bethesda, MD: NIH; 1990; 8: 1-19.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer Version 2.2013. nccn.org/index.asp. Accessed October 31, 2013.
3. Fisher B, Anderson S, Bryant J, et al. Twenty year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med. 2002; 347: 1233-1241.
4. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005. 366: 2087-2106.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378: 1707-1716.
6. Nemoto T, Patel JK, Rosner D, Dao TL, Schuh M, Penetrante R,. Factors affecting recurrence in lumpectomy without irradiation for breast cancer. Cancer. 1991; 67: 2079-2082.
7. Lim M, Bello J, Gelman R, et al. A prospective study of conservative surgery without radiation therapy in select patients with stage I breast cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1149-1154.
8. Holli K, Hietanen P, Saaristo R, Huhtala H, Hakama M, Joensuu H,. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol. 2009; 27: 927-932.
9. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002; 20: 4141-4149.
10. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 963-970.
11. Winzer KJ, Sauerbrei W, Braun M, et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2×2 randomised clinical trial in patient with low risk of recurrence. Eur J Cancer. 2010; 46: 95-101.
12. Potter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 334-340.
13. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 971-977.
14. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013; 31: 2382-2387.
15. Ceilley E, Jagsi R, Goldberg SI, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys. 2005; 61: 365-373.
16. Morrow M, White J, Moughan J, et al. Factors predicting the use of breast conserving therapy in stage I and II breast carcinoma. J Clin Oncol. 2001; 19: 2254-2262.
17. Nattinger AB GM, Veum J, Yahnke D, et al. Geographic variation in the use of breast-conserving treatment of breast cancer. N Engl J Med. 1992; 326: 1147-1149.
18. Cohen L,. Radiotherapy in breast cancer I: the dose-time relationship-theoretical considerations. Br J Radiol. 1952; 25: 636-642.
19. Douglas BG, Castro JR,. Novel fractionation schemes and high linear energy transfer. Prog Exp Tumor Res. 1984; 28: 152-165.
20. Whelan TJ, Kim DH, Sussman J,. Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol. 2008; 18: 257-264.
21. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002; 94: 1143-1150.
22. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362: 513-520.
23. Ashworth A, Kong W, Whelan T, Mackillop WJ,. A population-based study of the fractionation of postlumpectomy breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86: 51-57.
24. Curry H, Jagsi R,. Utilization of hypofractionation in an insured population. Paper presented at: 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO); September 22-25, 2013; Atlanta, Georgia.
25. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25: 3259-3265.
26. Ben-David MA, Sturtz DE, Griffith KA, et al. Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: the University of Michigan experience. Breast J. 2007; 13: 392-400.
27. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005; 75: 9-17.
28. Yarnold J, Bloomfield D, LeVay J, et al. Prospective randomized trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in women with early breast cancer (FAST) trial [abstract]. Clin Oncol. 2004; 16: S30. Abstract P3.02.
29. Freedman GM, Anderson PR, Goldstein LJ, et al. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys. 2007; 68: 347-353.
30. Clark RM, McCulloch PB, Levine MN, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst. 1992; 84: 683-689.
31. Liljegren G, Holmberg L, Bergh A, et al. Ten-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999; 17: 2326-2333.
32. Vicini FA, Kestin L, Chen P, et al. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst. 2003; 95: 1205-1211.
33. Vicini FA, Kestin LL, Goldstein NS,. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis. Int J Radiat Oncol Biol Phys. 2004; 60: 722-730.
34. Bankhead C,. Accelerated partial breast irradiation: more data needed, researchers say. J Natl Cancer Inst. 2003; 95: 259-261.
35. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy for patients with early-stage breast cancer: updated results of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 2001; 51 (3 suppl 1): 2-3.
36. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001; 12: 997-1003.
37. Holland R, Veling SHJ, Mravunac M, et al. Histologic multifocality of T-is, T1-2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer. 1985; 56: 979-990.
38. Vaidya JS, Vyas JJ, Chinoy RF, et al. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996; 74: 820-824.
39. Morimoto T, Okazaki K, Komaki K, et al. Cancerous residue in breast-conserving surgery. J Surg Oncol. 1993; 52: 71-76.
40. Fentiman IS, Poole C, Tong D, et al. Iridium implant treatment without external radiotherapy for operable breast cancer: a pilot study. Eur J Cancer. 1991; 27: 447-450.
41. Fentiman IS, Poole C, Tong D, et al. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer. 1996; 32A: 608-611.
42. Shah C, Antonucci JV, Wilkinson JB, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 2011; 100: 210-214.
43. Benitez PR, Chen PY, Vicini FA, et al. Partial breast irradiation in breast-conserving therapy by way of interstitial brachytherapy. Am J Surg. 2004; 188: 355-364.
44. King TA, Bolton JS, Kuske RR, et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis,1,2 breast cancer. Am J Surg. 2000; 180: 299-304.
45. Wazer DE, Berle L, Graham R, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 889-897.
46. Lawenda BD, Taghian AG, Kachnic LA, et al. Dose-volume analysis of radiotherapy for T1N0 invasive breast cancer treated by local excision and partial breast irradiation by low-dose rate interstitial implant. Int J Radiat Oncol Biol Phys. 2003; 56: 671-680.
47. Krishnan L, Jewell WR, Tawfik OW, et al. Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer. Breast J. 2001; 7: 91-96.
48. Arthur DW, Koo D, Zwicker RD, et al. Partial breast brachytherapy after lumpectomy: low dose rate and high dose rate experience. Int J Radiat Oncol Biol Phys. 2003; 56: 681-689.
49. Kuske RR, Bolton JS,. A Phase I/II Trial to Evaluate Brachytherapy as the Sole Method of Radiation Therapy for Stage I and II Breast Carcinoma. Radiation Therapy Oncology Group Publication no. 1055. Philadelphia, PA: Radiation Therapy Oncology Group; 1995.
50. Hattangadi JA, Powell SN, Macdonald SM, et al. Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012; 83: 791-800.
51. Hannoun-Levi JM, Polgar C, Van Limbergen E,. In regard to Hattangadi et al (Int J Radiat Oncol Biol Phys. Epub Nov 17, 2011): accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012; 83: 481-482.
52. Polgar C, Fodor J, Major T, Sulyok Z, Kasler M,. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol. 2013; 108: 197-202.
53. Keisch M, Vicini F, Scroggins T, et al. Thirty month results with the MammoSite breast brachytherapy applicator: cosmesis, toxicity, and local control in partial breast irradiation [abstract]. Int J Radiat Oncol Biol Phys. 2004; 60 (1 suppl 1): S272.
54. Keisch M, Vicini F, Kuske R, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys. 2003; 55: 289-293.
55. Shah NM, Tenenholz T, Arthur D, et al. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis. Cancer. 2004; 101: 727-734.
56. Smith GL, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012; 307: 1827-1837.
57. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg. 2009; 209: 269-277.
58. Cuttino LW, White JR, Rabinovitch R, et al. Accelerated partial breast irradiation: trial by media or by science? Int J Radiat Oncol Biol Phys. 2012; 83: 1075-1077.
59. Evans SB, Kaufman SA, Price LL, et al. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: incidence, pathologic anatomy, and contributing factors. Int J Radiat Oncol Biol Phys. 2006; 65: 333-339.
60. Shah C, Khwaja S, Badiyan S, et al. Brachytherapy-based partial breast irradiation is associated with low rates of complications and excellent cosmesis. Brachytherapy. 2013; 12: 278-284.
61. Arthur DW, Vicini FA, Todor DA, Julian TB, Cuttino LW, Mukhopadhyay ND,. Contura multi-lumen balloon breast brachytherapy catheter: comparative dosimetric findings of a phase 4 trial. Int J Radiat Oncol Biol Phys. 2013; 86: 264-269.
62. Lu SM, Scanderbeg DJ, Barna P, et al. Evaluation of two intracavitary high-dose-rate brachytherapy devices for irradiating additional and irregularly shaped volumes of breast tissue. Med Dosim. 2012; 37: 9-14.
63. Yashar CM, Scanderbeg D, Kuske R, et al. Initial clinical experience with the Strut-Adjusted Volume Implant (SAVI) breast brachytherapy device for accelerated partial-breast irradiation (APBI): first 100 patients with more than 1 year of follow-up. Int J Radiat Oncol Biol Phys. 2011; 80: 765-770.
64. Manoharan SR, Rodriguez RR, Bobba VS, et al. Dosimetry evaluation of SAVI-based HDR brachytherapy for partial breast irradiation. J Med Phys. 2010; 35: 131-136.
65. Veronesi U, Orecchia R, Luini A, et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer. 2001; 37: 2178-2183.
66. Orecchia R, Ciocca M, Lazzari R, et al. Intraoperative radiation therapy with electrons (ELIOT) in early-stage breast cancer. Breast. 2003; 12: 483-490.
67. Veronesi U, Gatti G, Luini A, et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Arch Surg. 2003; 138: 1253-1256.
68. Leonardi MC, Ivaldi GB, Santoro L, et al. Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment. Tumori. 2012; 98: 324-330.
69. Johnson K,. Intraoperative Breast Radiotherapy: The 5-year Lesson. Medscape Medical News, April 22, 2013. medscape.com/viewarticle/802873. Accessed October 31, 2013.
70. Kimple RJ, Klauber-DeMore N, Kuzmiak CM, et al. Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer. Ann Surg Oncol. 2011; 18: 939-945.
71. Vanderwalde NA, Jones EL, Kimple RJ, et al. Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria. Cancer. 2013; 119: 1736-1743.
72. Vaidya JS, Baum M, Tobias JS, et al. The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol. 2002; 28: 447-454.
73. Vaidya JS, Baum M, Tobias JS, et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol. 2001; 12: 1075-1080.
74. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010; 376: 91-102.
75. Ribeiro GG, Dunn G, Swindell R, et al. Conservation of the breast using two different radiotherapy techniques: interim report of a clinical trial. Clin Oncol (R Coll Radiol). 1990; 2: 27-34.
76. Ribeiro GG, Magee B, Swindell R, Harris M, Banerjee SS,. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol). 1993; 5: 278-283.
77. Formenti SC, Rosenstein B, Skinner KA, et al. T1 stage breast cancer: adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients-Pilot feasibility study. Radiology. 2002; 222: 171-178.
78. Truong MT, Hirsch AE, Formenti SC,. Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer. Clin Breast Cancer. 2003; 4: 253-263.
79. Wernicke AG, Gidea-Addeo D, Magnolfi C, et al. External beam partial breast irradiation following breast-conserving surgery: preliminary results of cosmetic outcome of NYU 00-23. 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Philadelphia, PA, 2006. Int J Radiat Oncol Biol Phys. 2006; 66: S32A-S3A.
80. Baglan KL, Sharpe MB, Jaffray D, et al. Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2003; 55: 302-311.
81. Vicini FA, Remouchamps V, Wallace M, et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003; 57: 1247-1253.
82. Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2007; 69: 1124-1130.
83. National Surgical Adjuvant Breast and Bowel Project (NASBP)/Radiation Therapy Oncology Group (RTOG). A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer. NSABP Protocol B-39/RTOG Protocol 0413. Philadelphia, PA: NASBP/RTOG; 2007.
84. Weed DW, Edmundson GK, Vicini FA, Chen PY, Martinez AA,. Accelerated partial breast irradiation: a dosimetric comparison of three different techniques. Brachytherapy. 2005; 4: 121-129.
85. Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009; 75: 1290-1296.
86. Leonard KL, Hepel JT, Hiatt JR, Dipetrillo TA, Price LL, Wazer DE,. The effect of dose-volume parameters and interfraction interval on cosmetic outcome and toxicity after 3-dimensional conformal accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013; 85: 623-629.
87. Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010; 76: 71-78.
88. Wolmark N, Curran WJ, Vicini F, et al. Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" (Int J Radiat Oncol Biol Phys 2009;75:1290-1296) [letter]. Int J Radiat Oncol Biol Phys. 2010; 77: 317.
89. Bentzen SM, Yarnold JR,. Reports of unexpected late side effects of accelerated partial breast irradiation-radiobiological considerations. Int J Radiat Oncol Biol Phys. 2010; 77: 969-973.
90. Arthur D, Vicini F, Kuske RR, et al. Accelerated partial breast irradiation: an updated report of the American Brachytherapy Society. Brachytherapy. 2002; 1: 184-190.
91. Arthur DW,. Accelerated partial breast irradiation: a change in treatment paradigm for early stage breast cancer. J Surg Oncol. 2003; 84: 185-191.
92. Haffty BG, Buchholz TA, McCormick B,. Should intensity-modulated radiation therapy be the standard of care in the conservatively managed breast cancer patient? J Clin Oncol. 2008; 26: 2072-2074.
93. Harsolia A, Kestin L, Grills I, et al. In clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 1375-1380.
94. Vicini FA, Sharpe M, Kestin L, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 54: 1336-1344.
95. Lo YC, Yasuda G, Fitzgerald TJ, et al. Intensity modulation for breast treatment using static multi-leaf collimators. Int J Radiat Oncol Biol Phys. 2000; 46: 187-194.
96. Kestin LL, Sharpe MB, Frazier RC, et al. Intensity modulation to improve dose uniformity with tangential breast radiotherapy: initial clinical experience. Int J Radiat Oncol Biol Phys. 2000; 48: 1559-1568.
97. Chui CS, Hong L, Hunt M, et al. A simplified intensity modulated radiation therapy technique for the breast. Med Phys. 2002; 29: 522-529.
98. van Asselen B, Schwarz M, van Vliet-Vroegindeweij C, et al. Intensity-modulated radiotherapy of breast cancer using direct aperture optimization. Radiother Oncol. 2006; 79: 162-169.
99. Freedman GM, Anderson PR, Li JS, et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol. 2006; 29: 66-70.
100. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. Joint Annual Meeting of the Canadian Association of Radiation Oncology/Canadian Organization of Medical Physicists. Toronto, Canada, 2007. J Clin Oncol. 2008; 26: 2085-2092.
101. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007; 82: 254-264.
102. Smith BD, Pan IW, Shih YC, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011; 103: 798-809.
103. Easson EC,. Postoperative radiotherapy in breast cancer. In:, Forrest AP, Kunkler PB, eds. Evolution of Postoperative Radiotherapy. Edinburgh, UK: E&S Livingston; 1968: 118-127.
104. Host H, Brennhovd IO,. The effect of postoperative radiotherapy in breast cancer. Int J Radiat Oncol Biol Phys. 1977; 2: 1061-1067.
105. Tapley N, Spanos WJ, Fletcher GH, et al. Results in patient with breast cancer treated by radical mastectomy and post-operative irradiation with no adjuvant chemotherapy. Cancer. 1983; 49; 1316-1319.
106. Fisher B, Slack NH, Cavanaugh PJ, et al. Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial. Ann Surg. 1970; 172: 711-730.
107. Cooper MR, Rhyne AL, Muss HB, et al. A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer. 1981; 47: 2833-2839.
108. Ahmann DL, O'Fallon JR, Scanlon PW, et al. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol. 1982; 5: 371-381.
109. Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without BCG and with or without irradiation in operable breast cancer. Cancer. 1984; 53: 384-389.
110. Velez-Garcia E, Carpenter JT Jr, Moore M, et al. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer. 1992; 28A: 1833-1837.
111. Griem KL, Henderson IC, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol. 1987; 5: 1546-1555.
112. McArdle CS, Crawford D, Dykes EH, et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg. 1986; 73: 264-266.
113. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987; 71: 15-29.
114. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994; 12: 447-453.
115. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials. N Engl J Med. 1995; 333: 1444-1455.
116. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000; 355: 1757-1770.
117. Hojris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet. 1999; 354: 1425-1430.
118. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999; 353: 1641-1648.
119. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Nat Cancer Inst. 2005; 97: 116-126.
120. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML,. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000; 18: 1220-1229.
121. Van de Steene J, Soete G, Storme G,. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol. 2000; 55: 263-272.
122. Pierce LJ,. The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol. 2005; 23: 1706-1717.
123. Overgaard M,. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999; 9: 292-299.
124. Benson EA, Thorogood J,. The effect of surgical technique on local recurrence rates following mastectomy. Eur J Surg Oncol. 1986; 12: 267-271.
125. Haagensen CD,. Diseases of the Breast. 3rd ed. Philadelphia, PA: WB Saunders; 1996.
126. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999; 17: 1689-1700.
127. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000; 18: 2817-2827.
128. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E,. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 1337-1347.
129. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004; 22: 4247-4254.
130. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19: 1539-1569.
131. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ,. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999; 44: 989-990.
132. Taylor ME, Haffty BG, Shank BM, et al. Postmastectomy radiotherapy. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000; 215 (suppl): 1153-1170.
133. Truong PT, Olivotto IA, Whelan TJ, Levine M,; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ. 2004; 170: 1263-1273
134. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer Version 3.2013. nccn.org/index.asp. Accessed October 31, 2013.
135. Overgaard M, Nielsen HM, Overgaard J,. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended by international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007; 82: 247-253.
136. Mignano JE, Gage I, Piantadosi S, et al. Local recurrence after mastectomy in patient with T3N0 breast carcinoma treated without postoperative irradiation [abstract]. Breast Cancer Res Treat. 1996; 41: 255.
137. Helinto M, Blomqvist C, Heikkila P, Joensuu H,. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed? Radiother Oncol. 1999; 52: 213-217.
138. Floyd SR, Buchholz TA, Haffty BG, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006; 66: 358-364.
139. Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006; 24: 3927-3932.
140. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003; 21: 1205-1213.
141. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005; 62: 1035-1039.
142. Truong PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA,. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys. 2005; 62: 175-182.
143. Freedman GM, Fowble BL, Hanlon AL, et al. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys. 1998; 41: 599-605.
144. Truong PT, Olivotto IA, Speers CH, et al. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 797-804.
145. Childs SK, Chen YH, Duggan MM, et al. Surgical margins and the risk of local-regional recurrence after mastectomy without radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 84: 1133-1138.
146. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference. J Clin Oncol. 2008; 26: 791-797.
147. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004; 22: 4691-4699.
148. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 1004-1009.
149. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012; 30: 3960-3966.
150. Haffty BG, Hunt KK, Harris JR, Buchholz TA,. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011; 29: 4479-4481.
151. Nguyen-Tan PF, Vincent L, Methot F, et al. The incidence of supraclavicular failure in patients with T1-2 breast cancer and four or more positive nodes treated by conservative surgery and tangential breast irradiation without regional nodal irradiation [abstract]. Int J Radiat Oncol Biol Phys. 1998; 42 (suppl 1): 249.
152. Buchholz TA,. Internal mammary lymph nodes: to treat or not to treat. Int J Radiat Oncol Biol Phys. 2000; 46: 801-803.
153. Freedman G, Fowble BL, Nicolaou N, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys. 2000; 46: 805-814.
154. Marks L, Hebert ME, Bentel G, Spencer DP, Sherouse GW, Prosnitz LR,. To treat or not to treat the internal mammary nodes: a possible compromise. Int J Radiat Oncol Biol Phys. 1994; 29: 903-909.
155. Taghian A, Jagsi R, Makris A, Goldberg S, Ceilley E, Grignon L, Powell S,. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys. 2004; 60: 706-714.
156. Jagsi R, Pierce L,. Radiation therapy to the internal mammary nodal region in breast cancer: the debate continues. Int J Radiat Oncol Biol Phys. 2013; 86: 813-815.
157. Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E,. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol. 1998; 16: 2625-2631.
158. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005; 97: 419-424.
159. Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005; 63: 214-223.
160. Jagsi R, Griffith KA, Koelling T, et al. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007; 109: 650-657.
161. Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006; 24: 4100-4106.
162. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007; 99: 365-375.
163. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368: 987-998.
164. Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006; 24: 4594-4602.
165. Mamonuas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative estrogen-receptor positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010; 28: 1677-1683.
166. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26: 1419-1426.
167. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S,. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011; 29: 2852-2858.
168. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H,. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28: 1684-1691.
169. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26: 2373-2378.